Tebideutorexant

Tebideutorexant^[2] (developmental code names JNJ-61393215, JNJ-3215) is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders.^[3][4][5][6] The drug was originated and developed by Janssen Pharmaceuticals.^[3]

Tebideutorexant

Clinical data
Other names	JNJ-61393215; JNJ-3215
Routes of administration	Oral
Drug class	Orexin receptor antagonist
Pharmacokinetic data
Elimination half-life	14–25 hours[1]
Identifiers
IUPAC name [(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone
CAS Number	1637681-55-0
PubChem CID	139030979
ChemSpider	76117730
UNII	DQ7SMA8TWV
ChEMBL	ChEMBL4776719
Chemical and physical data
Formula	C23H18F4N4O2
Molar mass	458.417 g·mol−1
3D model (JSmol)	Interactive image
SMILES [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H]
InChI InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2 Key:HUKWIAXQBOHZIX-USKNZQBOSA-N

It is an orally active compound and acts as a selective antagonist of the orexin OX₁ receptor (1-SORA).^[4][5][6] Preliminary clinical findings suggest that tebideutorexant may have anti-panic effects in humans.^[4][5] The elimination half-life of tebideutorexant is 13.6 to 24.6 hours.^[1]

As of June 2023, tebideutorexant is in phase 2 clinical trials for the treatment of major depressive disorder while no further development has been reported for treatment of panic disorder and other anxiety disorders.^[3] In 2025, a phase 2a, double-blind, placebo-controlled trial in adults with major depressive disorder and anxious distress found that adjunctive tebideutorexant did not significantly improve depressive symptoms on the Hamilton Rating Scale for Depression or anxiety on the Hamilton Anxiety Rating Scale compared with placebo.^[7]

See also

• List of investigational antidepressants § Orexin receptor antagonists
• List of investigational anxiolytics